GEMODYVEQ Trademark

Trademark Overview

On Tuesday, May 5, 2020, a trademark application was filed for GEMODYVEQ with the United States Patent and Trademark Office. The USPTO has given the GEMODYVEQ trademark a serial number of 88902183. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 30, 2023. This trademark is owned by Pfizer Inc.. The GEMODYVEQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; pharmaceutical preparations for the treatment of muscular dystrophy
gemodyveq

General Information

Serial Number88902183
Word MarkGEMODYVEQ
Filing DateTuesday, May 5, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 30, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 4, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; pharmaceutical preparations for the treatment of muscular dystrophy

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, May 17, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 100012192
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, October 30, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, October 30, 2023ABANDONMENT - NO USE STATEMENT FILED
Thursday, April 6, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, April 6, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, April 6, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, April 6, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, April 6, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, March 1, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 28, 2023SOU EXTENSION 5 GRANTED
Friday, February 10, 2023SOU EXTENSION 5 FILED
Tuesday, February 28, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, February 10, 2023SOU TEAS EXTENSION RECEIVED
Saturday, September 10, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 8, 2022SOU EXTENSION 4 GRANTED
Thursday, September 8, 2022SOU EXTENSION 4 FILED
Thursday, September 8, 2022SOU TEAS EXTENSION RECEIVED
Saturday, March 19, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 17, 2022SOU EXTENSION 3 GRANTED
Thursday, March 17, 2022SOU EXTENSION 3 FILED
Thursday, March 17, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, September 15, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 13, 2021SOU EXTENSION 2 GRANTED
Monday, September 13, 2021SOU EXTENSION 2 FILED
Monday, September 13, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, March 2, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, February 26, 2021SOU EXTENSION 1 GRANTED
Friday, February 26, 2021SOU EXTENSION 1 FILED
Friday, February 26, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, September 29, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 4, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 4, 2020PUBLISHED FOR OPPOSITION
Wednesday, July 15, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, June 25, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, June 23, 2020ASSIGNED TO EXAMINER
Sunday, May 17, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, May 8, 2020NEW APPLICATION ENTERED

Related Keywords

gemodyveq preparations pharmaceutical disorders treatment stroke pain obesity hypertension skin growth